Complete response of leptomeningeal carcinomatosis secondary to breast cancer |
| |
| Affiliation: | 1. Radiation Oncology Department, Hospital Universitary of Geneva, Avenue de La Roseraie 53, 1205, Genève, Suisse, Switzerland;2. Radiation Oncology Department, Centre de Haute Energie, 10 Boulevard Pasteur, 06000, Nice, France;3. University Pierre and Marie Curie, Paris Sorbonne University, 91-105 Boulevard de L’Hôpital, 75013, Paris, France |
| |
| Abstract: | Leptomeningeal carcinomatosis (LC) is an unmet medical need associated with death in 4–6 weeks without treatment, delayed by 4 months in some patients with favorable prognosis and aggressive multimodal therapy. Unfortunately, most clinical trials excluded patients with LC, and the best management remains unknown.Here we present the first report of a LC secondary to HR positive breast cancer with a complete response to CDK4/6 inhibitors abemaciclib, letrozole and hippocampal-avoidance whole-brain radiotherapy. |
| |
| Keywords: | Meningeal carcinomatosis Metastatic breast neoplasms CDK4/6 cell-cycle inhibitors Hippocampal-avoidance whole brain radiotherapy Abemaciclib |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
